Heron Therapeutics Inc (HRTX) USD0.01
Sell:$2.30Buy:$2.38
$0.03
(1.32%)
- This stock can be held in a
Stocks and Shares ISA$0.03
(1.32%)$0.03
(1.32%)Company Information
About this company
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.
Key people
Key facts
- EPICHRTX
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS4277461020
- Market cap$335.13m
- Employees122
- Shares in issue152.33m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.